Journal of Isfahan Medical School

Journal of Isfahan Medical School

Epidemiological Survey of the Patients with Bullous Pemphigoid Hospitalized in Alzahra Hospital, Isfahan, Iran, during the Years 2006-2015

Document Type : Original Article (s)

Authors
Fatemeh Mokhtari 1
Fariba Iraji 2
Shiva Radfar 3
Ali Asilian 2
Gita Faghihi 2
Sayed Mohsen Hosseini 4
1 Associate Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4 Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Biostatics and Epidemiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
10.22122/jims.v36i507.10647
Abstract
Background: Bullous pemphigoid is one of the most common autoimmune blistering diseases. Incidence of bullous pemphigoid has been estimated 4 new cases per 100000, but new studies show that the incidence rate is increasing. The disease typically happens in the elderly people usually after 70 years. Annual mortality rate for bullous pemphigoid is reported up to 40%. The aim of this study was to evaluate epidemiological features of bullous pemphigoid in center of Iran.Methods: This was a cross-sectional study conducted in Alzahra hospital in Isfahan City. 69 patients with bullous pemphigoid hospitalized during the years 2008-2016 were studied.Findings: 59.45% of the patients were women. The mean and standard deviation of age was 68 ± 13 and 72 ± 14 years in woman and men, respectively (P = 0.01). Mucosal involvement was seen in 55.4%., and the most common underlying disease was hypertension (23.6%). 15.4% of women and 3.7% of men used furosemide, and the most commonly prescribed drugs were antihistamine (98%), antibiotics (97%), and topical (91%) and systemic (88.4%) corticosteroids, respectively. The mean and standard deviation of the dose of prednisolone was 54 ± 12 mg per day. Rise in serum blood sugar was reported in 30% of patients, and 3.6% of men and 15% of women needed intensive care unit (ICU) admission. 42.9% of men and 44.4% of women had relapse after discharge, and 38.64% of patients died during one-year follow-up.Conclusion: It seems that patients with bullous pemphigoid need careful follow up, especially during treatment, and at least for one year, because of their age (> 60), underlying diseases, type of treatment (corticosteroid use), and high mortality and relapsing rates in the first year after diagnosis.
Keywords
Bullous pemphigoid
Epidemiology
Age
Sex
Treatment
Complication
  1. Chalmers JR, Wojnarowska F, Kirtschig G, Nunn AJ, Bratton DJ, Mason J, et al. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. Br J Dermatol 2015; 173(1): 227-34.
  2. Cortes B, Khelifa E, Clivaz L, Cazzaniga S, Saurat JH, Naldi L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology 2012; 225(4): 320-5.
  3. Banihashemi M, Zabolinejad N, Vahabi S, Razavi HS. Survey of bullous pemphigoid disease in northern Iran. Int J Dermatol 2015; 54(11): 1246-9.
  4. Cozzani E, Gasparini G, Burlando M, Drago F, Parodi A. Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects. Autoimmun Rev 2015; 14(5): 438-45.
  5. Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 2015; 172(4): 867-77.
  6. Lo SA, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 2013; 31(4): 391-9.
  7. Esmaili N, Hallaji Z, Soori T, Chams DC. Bullous pemphigoid in Iranian patients: a descriptive study on 122 cases. Acta Med Iran 2012; 50(5): 335-8.
  8. Kibsgaard L, Bay B, Deleuran M, Vestergaard C. A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre. Acta Derm Venereol 2015; 95(3): 307-11.
  9. Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389(10079): 1630-8.
  10. Cai SC, Allen JC, Lim YL, Chua SH, Tan SH, Tang MB. Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre. Br J Dermatol 2014; 170(6): 1319-26.
  11. Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132(8): 1998-2004.
  12. Thorslund K, Seifert O, Nilzen K, Gronhagen C. Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res 2017; 309(9): 721-7.
  13. Daneshpazhooh M, Chams-Davatchi C, Payandemehr P, Nassiri S, Valikhani M, Safai-Naraghi Z. Spectrum of autoimmune bullous diseases in Iran: A 10-year review. Int J Dermatol 2012; 51(1): 35-41.
  14. Pankakoski A, Sintonen H, Ranki A, Kluger N. Comorbidities of bullous pemphigoid in a Finnish cohort. Eur J Dermatol 2018; 28(2): 157-61.
  15. Ruocco E, Wolf R, Caccavale S, Brancaccio G, Ruocco V, Lo SA. RETRACTED: Bullous pemphigoid: associations and management guidelines: Facts and controversies. Clin Dermatol 2013; 31(4): 400-12.
  16. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28(9): 1133-40.
  17. Bernard P, Borradori L. Pemphigoid group. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 4th ed. Philadelphia, PA: Elsevier; 2018. p. 518-9.
  18. Jeon HW, Yun SJ, Lee SC, Won YH, Lee JB. Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea. Ann Dermatol 2018; 30(1): 13-9.
Journal of Isfahan Medical School
Volume 36, Issue 507 - Serial Number 507
November and December 2019
Pages 1491-1497

  • Receive Date 12 August 2018
  • Accept Date 06 April 2022